Abstract
Hyperornithinemia due to ornithine aminotransferase (OAT) deficiency is associated with gyrate atrophy of the choroid and retina. Patients usually become virtually blind by age 55. Treatment includes a low arginine diet and pharmacological doses of pyridoxine (vitamin B6). Long term compliance to an arginine-restricted diet, especially when started at a young age, can slow the progression of the chorioretinal lesions and loss of vision. Rarely, neonates can present with hyperammonemic encephalopathy, hypoargininemia, and hypoornithinemia and require arginine supplementation. In the hyperornithinemia, hyperammonemia, and homocitrullinuria (HHH) syndrome there is a wide spectrum of clinical manifestations, most of which are related to the toxicity of hyperammonemia. Progressive spastic paraparesis is often a late complication. Patients have a marked elevation of plasma ornithine associated with hyperammonemia and increased urinary excretion of homocitrulline. HHH results from a defect in the import of ornithine into the mitochondrion and consequent urea synthesis malfunction. Treatment is similar to that for patients with urea cycle disorders.
A newly recognized disorder, Δ 1-pyrroline-5-carboxylate synthase (P5CS) deficiency, has been described in two siblings with progressive neurodegeneration and peripheral neuropathy, joint laxity, skin hyperelasticity and bilateral subcapsular cataracts. Their metabolic phenotype includes mild hyperammonemia, hypoornithinemia, hypocitrullinemia, hypoargininemia and hypoprolinemia. This disorder underscores the importance of low levels of amino acids as markers of metabolic disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Takahashi O, Hayasaka S, Kiyosawa M et al (1985) Gyrate atrophy of choroid and retina complicated by vitreous hemorrhage. Jpn J Ophthalmol 29:170–176
Cleary MA, Dorland L, de Koning TJ et al (2005) Ornithine aminotransferase deficiency: diagnostic difficulties in neonatal presentation. J Inherit Metab Dis 28:673–679
Webster M, Allen J, Rawlinson D et al (1999) Ornithine Aminotransferase Deficiency presenting with hyperammonaemia in a premature newborn. J Inherit Metab Dis 22[Suppl 1]:80
Champion MP, Bird S, Fensom T, Dalton RN (2002) Ornithine aminotransferase deficiency (gyrate atrophy) presenting with hyperammonaemic encephalopathy. J Inherit Metab Dis 25[Suppl 1]:29
Wilson DJ, Weleber RG, Green WR (1991) Ocular clinicopathologic study of gyrate atrophy. Am J Ophthalmol 111:24–33
Arshinoff SA, McCulloch JC, Matuk Y et al (1979) Amino-acid meta bolism and liver ultrastructure in hyperornithinemia with gyrate atrophy of the choroid and retina. Metabolism 28:979–988
Kaiser-Kupfer MI, Kuwabara T, Askanas V (1981) Systemic manifestations of gyrate atrophy of the choroid and retina. Ophthalmology 88:918–928
Valtonen M, Nanto-Salonen K, Jaaskelainen S et al (1999) Central nervous system involvement in gyrate atrophy of the choroids and retina with hyperornithinaemia. J Inherit Metab Dis 22:855–866
Peltola KE, Jaaskelainen S, Heinonen OJ et al (2002) Peripheral nervous system in gyrate atrophy of the choroid and retina with hyperornithinemia. Neurology 59:735–740
Trijbels JMF, Sengers RCA, Bakkaren JAJM et al (1977) L-Ornithineketoacidtransaminase deficiency in cultured fibroblasts of a patient with hyperornithinemia and gyrate atrophy of the choroids and retina. Clin Chim Acta 79:371–377
Wang T, Lawler AM, Steel G et al (1995) Mice lacking ornithinedelta-aminotransferase have paradoxical neonatal hypoornithinaemia and retinal degeneration. Nat Genet 11:185–190
Vannas-Sulonen K, Simell O, Sipila I (1987) Gyrate atrophy of the choroid and retina. The ocular disease progresses in juvenile patients despite normal or near normal plasma ornithine concentration. Ophthalmology 94:1428–1433
Nanto-Salonen K, Komu M, Lundbom N et al (1999) Reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia. Neurology 53:303–307
Takki K (1974) Gyrate atrophy of the choroid and retina associated with hyperornithinaemia. Br J Ophthalmol 58:3
Ramesh V, Gusella JF, Shih VE (1991) Molecular pathology of gyrate atrophy of the choroid and retina due to ornithine aminotransferase deficiency. Mol Biol Med 8:81–94
Valle D, Walser M, Brusilow SW, Kaiser-Kupfer M (1980) Gyrate atrophy of the choroid and retina: amino acid metabolism and correction of hyperornithinemia with an arginine-deficient diet. J Clin Invest 65:371–378
McInnes RR, Arshinoff SA, Bell L et al (1981) Hyperornithinaemia and gyrate atrophy of the retina: improvement of vision during treatment with a low-arginine diet. Lancet 1:513–516
Kennaway NG, Weleber RG, Buist NRM (1980) Gyrate atrophy of the choroid and retina with hyperornithinemia: Biochemical and histologic studies and repsonse to vitamin B6. Am J Hum Genet 32:529
Hayasaka S, Saito T, Nakajima H et al (1985) Clinical trials of vitamin B6 and proline supplementation for gyrate atrophy of the choroids and retina. Br J Ophthalmol 69:283–290
Shih VE, Berson EL, Gargiulo M (1981) Reduction of hyperornithinemia with a low protein, low arginine diet and pyridoxine in patients with a deficiency of ornithine-ketoacid transaminase (OKT) activity and gyrate atrophy of the choroid and retina. Clin Chim Acta 113:243–251
Kaiser-Kupfer MI, Caruso RC, Valle D, Reed GF (2004) Use of an arginine-restricted diet to slow progression of visual loss in patients with gyrate atrophy. Arch Ophthalmol 122:982–984
Kaiser-Kupfer MI, Caruso RC, Valle D (2002) Gyrate atrophy of the choroid and retina: further experience with long-term re duction of ornithine levels in children. Arch Ophthalmol 120:146–153
Santinelli R, Costagliola C, Tolone C et al (2004) Low-protein diet and progression of retinal degeneration in gyrate atrophy of the choroid and retina: a twenty-six-year follow-up. J Inherit Metab Dis 27:187–196
Heinanen K, Nanto-Salonen K, Komu M et al (1999) Creatine corrects muscle 31P spectrum in gyrate atrophy with hyperornithinaemia. Eur J Clin Invest 29:1060–1065
Elpeleg N, Korman SH (2001) Sustained oral lysine supplementation in ornithine delta-aminotransferase deficiency. J Inherit Metab Dis 24:423–424
Shih VE, Efron ML, Moser HW (1969) Hyperornithinemia, hyperammonemia, and homocitrullinuria: A new disorder of amino acid metabolism associated with myoclonic seizures and mental retardation. Am J Dis Child 117:83
Shih VE, Laframboise R, Mandell R, Pichette J (1992) Neonatal form of the hyperornithinemia, hyperammonemia and homocitrullinuria (HHH) syndrome and prenatal diagnosis. Prenat Diagn 12:717–723
Salvi S, Dionisi-Vici C, Bertini E et al (2001) Seven novel mutations in the ORNT1 gene (SLC25A15) in patients with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome. Hum Mutat 18:460
Dionisi Vici C, Bachmann C, Gambarara M et al (1987) Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome: low creatine excretion and effect of citrulline, arginine, or ornithine supplement. Pediatr Res 22:364–367
Smith L, Lambert MA, Brochu P et al (1992) Hyperornithinemia, hyperammonemia, homocitrullinuria (HHH) syndrome: presentation as acute liver disease with coagulopathy. J Pediatr Gastroenterol Nutr 15:431–436
Tuchman M, Knopman DS, Shih VE (1990) Episodic hyperammonemia in adult siblings with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome. Arch Neurol 47:1134–1137
Camacho JA, Obie C, Biery B et al (1999) Hyperornithinaemiahyperammonaemia-homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter. Nat Genet 22:151–158
Miyamoto T, Kanazawa N, Kato S et al (2001) Diagnosis of Japanese patients with HHH syndrome by molecular genetic analysis: a common mutation, R179X. J Hum Genet 46:260–262
Shih VE, Mandell R, Herzfeld A (1982) Defective ornithine metabolism in cultured skin fibroblasts from patients with the syndrome of hyperornithinemia, hyperammonemia and homocitrullinuria. Clin Chim Acta 118:149
Chadefaux B, Bonnefont JP, Shih VE, Saudubray JM (1989) Potential for the prenatal diagnosis of hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome. Am J Med Genet 32:264
Zammarchi E, Ciani R, Pasquini E et al (1997) Neonatal onset of hyperornithinemia-hyperammonemia-homocitrullinuria syndrome with favourable outcome. J Pediatr 131:440–443
Gaye AM, Wong PWK, Kang DS et al (1983) Treatment of hyperornithinemia, hyperammonemia and homocitrullinuria (HHH) during pregnancy. Clin Res 31:787A
Baumgartner MR, Rabier D, Nassogne MC et al (2005) Delta1-pyrroline-5-carboxylate synthase deficiency: Neurodegeneration, cataracts and connective tissue manifestations combined with hyperammonemia and reduced ornithine, citrulline, arginine and proline. Eur J Pediatr 164:31–36
Baumgartner MR, Hu CA, Almashanu S et al (2000) Hyperammonemia with reduced ornithine, citrulline, arginine and proline: a new inborn error caused by a mutation in the gene encoding delta(1)-pyrroline-5-carboxylate synthase. Hum Mol Genet 9:2853–2858
Wakabayashi Y, Yamada E, Hasegawa T, Yamada R (1991) Enzymological evidence for the indispensability of small intestine in the synthesis of arginine from glutamate. I. Pyrroline-5-carboxylate synthase. Arch Biochem Biophys 291:1–8
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Shih, V.E., Baumgartner, M.R. (2006). Disorders of Ornithine Metabolism. In: Fernandes, J., Saudubray, JM., van den Berghe, G., Walter, J.H. (eds) Inborn Metabolic Diseases. Springer, Berlin, Heidelberg . https://doi.org/10.1007/978-3-540-28785-8_22
Download citation
DOI: https://doi.org/10.1007/978-3-540-28785-8_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-28783-4
Online ISBN: 978-3-540-28785-8
eBook Packages: MedicineMedicine (R0)